Quantiferon Monitor Testing Sheds Light on Immune System Disparities between Multiple Sclerosis Patients and Healthy...

Area of Science:

• Immunology
• Neuroscience
• Biochemistry

Background:

• Multiple sclerosis (MS) involves complex immune dysregulation.
• Monitoring immune status in MS patients is crucial for treatment efficacy.
• Previous studies focused on Interferon-gamma (IFN-γ), necessitating broader immune marker investigation.

Purpose of the Study:

• To assess QuantiFERON Monitor (QFM) testing utility in MS patients.
• To analyze a panel of cytokines in healthy controls (HC), untreated progressive MS (pMS), and fingolimod-treated relapsing-remitting MS (fMS) patients.
• To identify potential cytokine biomarkers for MS progression and treatment response.

Main Methods:

• Blood samples from 280 participants (98 fMS, 96 pMS, 86 HC) were analyzed.
• Leukocyte stimulation followed by Interferon-gamma (IFN-γ) measurement via QuantiFERON Monitor (QFM).
• Screening of 15 cytokines using Luminex technology, with further analysis by ELISA.

Main Results:

• Elevated Interleukin-1 alpha (IL-1α) levels were observed in both pMS and fMS groups compared to HC.
• Significant differences in interleukin levels were found between patient groups.
• Interleukin-1 receptor antagonist (IL-1ra) and age were key predictors differentiating HC from pMS.
• IL-1ra, IL-1α, age, and EDSS distinguished pMS from fMS.

Conclusions:

• Cytokine profiles, particularly IL-1α and IL-1ra, show potential as biomarkers in MS.
• These biomarkers may aid in understanding MS progression and response to treatments like fingolimod.
• QFM testing and subsequent cytokine analysis offer insights into immune modulation in MS.